ActiveSight

Structural biology company announces availability of new service

Published in Medical Imaging Business Week, July 29th, 2004

ActiveSight has introduced a new service aimed at accelerating Hsp90 drug discovery and development by rapidly solving 3-D X-ray crystallographic structures of client compounds bound in the Hsp90 active site.

Human Hsp90, an important oncology target, is one of a class of proteins called chaperones, which function to facilitate the proper folding of other proteins. Many of the proteins Hsp90 helps to fold are themselves targets for anticancer drug development. Inhibition of Hsp90 disrupts the proper folding of these client proteins and thereby disrupts many of the pathways implicated in the growth of cancer.

"ActiveSight is pleased to be able to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Imaging Business Week

Source: Medical Imaging Business Week (2004-07-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry